Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation

Novel therapies in multiple myeloma

Disparities in myeloma: Closing the gap

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis

B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma

MRD-guided therapy debate

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Should every transplant eligible NDMM patient receive a transplant?

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients

Idecabtagene vicleucel for relapsed and refractory multiple myeloma

Vaccinations in myeloma patients including for COVID-19